Benzinga · Aug 7, 2026
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.
GL
NASDAQ · GLUE
Monte Rosa Therapeutics, Inc.
Healthcare · Biotechnology
$15.03
Down-$0.35 (-2.28%)
Updated Aug 19, 2026, 9:19 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.08B
- P/E ratio
- 56.25
- Dividend yield
- 0.00%
- 52-week range
- $4.52 – $25.77
- Volume
- 1.13M
- Avg. volume
- 1.57M
Price performance
GLUE price history
1M range · 21 trading sessions · Daily adjusted prices
GLUE closed at $15.03 after 21 trading sessions, down 36.39% for the selected period.
- Last close
- $15.03
- Period change
- -36.39%
- Period low
- $15.03
- Period high
- $23.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $15.03 | $15.38 | $14.70 | $15.03 | 1.13M |
| Aug 17, 2026 | $15.53 | $15.69 | $15.36 | $15.38 | 815.98K |
| Aug 14, 2026 | $15.72 | $15.83 | $15.3734 | $15.50 | 509.5K |
| Aug 13, 2026 | $16.08 | $16.25 | $15.79 | $15.84 | 682.35K |
| Aug 12, 2026 | $15.87 | $16.265 | $15.77 | $15.95 | 780.93K |
| Aug 11, 2026 | $15.97 | $16.075 | $15.54 | $15.76 | 704.41K |
| Aug 10, 2026 | $15.77 | $16.10 | $15.525 | $15.82 | 834.45K |
| Aug 7, 2026 | $15.817 | $16.12 | $15.65 | $15.88 | 1.03M |
| Aug 6, 2026 | $15.62 | $16.36 | $15.56 | $15.71 | 1.08M |
| Aug 5, 2026 | $16.25 | $16.855 | $15.085 | $15.61 | 1.98M |
| Aug 4, 2026 | $15.79 | $16.32 | $15.45 | $16.08 | 2.82M |
| Aug 3, 2026 | $16.64 | $17.17 | $15.21 | $15.38 | 2.32M |
| Jul 31, 2026 | $15.47 | $16.85 | $14.87 | $16.52 | 7.47M |
| Jul 30, 2026 | $22.09 | $22.69 | $21.21 | $22.68 | 1.69M |
| Jul 29, 2026 | $22.23 | $22.72 | $21.16 | $21.56 | 1.23M |
| Jul 28, 2026 | $22.56 | $22.64 | $21.11 | $22.04 | 1.33M |
| Jul 27, 2026 | $23.36 | $23.6475 | $22.535 | $22.56 | 1.1M |
| Jul 24, 2026 | $23.27 | $24.17 | $22.3701 | $22.78 | 870.56K |
| Jul 23, 2026 | $23.47 | $23.835 | $22.88 | $23.03 | 673.13K |
| Jul 22, 2026 | $23.675 | $23.83 | $23.085 | $23.79 | 734.62K |
| Jul 21, 2026 | $23.45 | $24.23 | $23.395 | $23.63 | 777.09K |
Latest GLUE news
The latest Smart Investors Daily articles mentioning GLUE.
Stock researchCompany · Overview
GLUE research
Overview
Company profile and research snapshot.
Company profile
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Wells Fargo | Overweight | — |
| Aug 3, 2026 | Wedbush | Outperform | — |
| Jun 30, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.
Benzinga · Aug 7, 2026
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $29 to $27.
ChartMill · Aug 6, 2026
Monte Rosa Therapeutics (NASDAQ:GLUE) Beats Q2 Revenue Estimates but Posts Wider Loss
Monte Rosa beats Q2 revenue estimates but wider EPS loss; stock edges up 3.2% premarket. Pipeline progresses with MRT-8102 and MRT-6160 trials.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
